). The proportion of patients treated with thrombolytic therapy diminished progressively after age 50 years (Fig 4) .
Among patients <60 years old, 50% received thrombolytic therapy, whereas among patients .60 years old, thrombolytic therapy was used in only 28% (P<.001).
Patients receiving thrombolytic therapy weighed more, were more likely to be men, and were more likely to have been transferred to the registry hospital from another hospital ( Table 2) . Patients receiving thrombolytic therapy were more likely to have ECG evidence localizing the infarction to the anterior, inferior, lateral, or posterior wall and less likely to have a nondiagnostic ECG or evidence of non-Q-wave infarction than those not treated with thrombolytic therapy. The The median time from onset of chest pain to hospital presentation for rTPA recipients was 95 minutes (1.6 hours). An additional 57 minutes (0.95 hours) (median) elapsed from hospital presentation to rTPA administration ("door-to-drug time"). Trend analyses from 1990 to 1993 showed lower median door-to-drug times in 1993 than in preceding years (Fig 7) . The site of rTPA initiation was most commonly (69.4%) the emergency department, but 23.2% of rTPA initiation took place in the coronary care unit. Among transferred patients receiving rTPA, the drug was usually (83.8%) begun before transport by the referring hospital. Major reasons cited for not administering rTPA were age >75 years, >6 hours since chest pain onset, use of other thrombolytic agent, a perceived contraindication to thrombolysis, and "physician preference." Primary angioplasty was rarely used (3.1%).
Concomitant Medications
Other frequently used pharmacological therapies recorded in the registry were oral aspirin, intravenous heparin, intravenous nitroglycerin, oral :-blockers, and oral calcium channel blockers (Table 4) . Of these, aspirin, intravenous heparin, and intravenous nitroglycerin were more commonly used in the thrombolytic group, and the other pharmacological agents were more (Table 4) . Coronary angioplasty and bypass surgery were also used liberally, especially in the thrombolytic group. Adverse Events In-Hospital Although the thrombolytic recipients had more frequent allergic reactions, drug-induced hypotension, peri-infarction arrhythmias, reinfarction, bleeding, and stroke, their mortality (unadjusted for baseline covariates) was less than half that of those not receiving thrombolytic therapy (5.9% versus 13.1%, P<.001) (Table 5). Among the thrombolytic recipients, hospital mortality was significantly higher for those presenting to the hospital later after chest pain onset than those presenting earlier (Fig 9) . The primary causes of death were cardiac in the thrombolytic and nonthrombolytic groups, and median durations of hospitalization were similar (Table 5) . Discussion
The National Registry of Myocardial Infarction is the largest voluntary database yet assembled of myocardial infarction patients in the thrombolytic era, and it reveals important insight into the current management of this common and potentially fatal illness. The registry documents the relatively low frequency of use of thrombolytic therapy in the United States, the long delay to presentation and treatment, a growing trend in the use of an accelerated rTPA dosing regimen, a lower than expected use of other proven pharmacological therapy, and a very high use of invasive procedures.
Frequency of Use of Thrombolytic Therapy
Thrombolytic therapy was used in 35% of registry patients, greater than the previously reported 20% use for myocardial infarction in the United States910 but substantially lower than the estimated 51% to 62% of patients with myocardial infarction potentially eligible for thrombolysis1""12 and the .70% of patients actually treated with thrombolytics as part of "usual care" in the recent third Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI-3) and fourth International Study of Infarct Survival (ISIS-4) trials. 13 The fact that registry hospitals were larger and more likely to have coronary care units and invasive capabilities (Table 1) may explain the more aggressive use of thrombolytic therapy in registry hospitals compared with prior estimates for US hospitals.
Nevertheless, even among registry hospitals, there was a tendency to target thrombolytic therapy toward relatively young patients presenting within the first few hours after infarction (Figs 4 and 5) . Meta-analyses14,15 of recent randomized trials have shown that the absolute mortality reduction with thrombolytic therapy is greater in elderly than in younger patients, and it is therefore now recommended that thrombolytic therapy not be withheld on the basis of age alone. When deciding whether to administer thrombolytic therapy to patients presenting relatively late after symptom onset, some practitioners may reason that the benefit of thrombolytic therapy diminishes rapidly over time, but its risk remains constant, thus favoring selective treatment of the earlier presenting patients. Although significant mortality reduction with the institution of thrombolytic therapy (rTPA) up to 12 hours after infarction has only recently been documented,16,17 it has long been appreciated that the benefit of lytic therapy extends to at least 6 hours after onset of symptoms.1" '8"19 However, only about one third of patients presenting within 4 to 6 hours of symptoms are treated (Fig 5) . Thus, with regard to age and elapsed time from onset of symptoms, it would seem that practitioners are not yet conforming to recommendations of recent trials when selecting patients for thrombolytic therapy.
Registry patients with non-Q-wave infarction or nondiagnostic ECGs rarely received thrombolytic therapy, whereas those with well-defined infarct location usually received thrombolytic therapy ( (Fig 9) , the National Heart, Lung, and Blood Institute has recently identified community interventions to reduce patient delay as a primary research target. Methods to reduce hospital delay ("door-to-drug time") by utilization of prehospital 12-lead ECG recording and streamlined emergency department protocols are also currently under intensive investigation. 25 Registry data provide valuable insight into the use of pharmacological therapy other than thrombolytics for acute myocardial infarction. Aspirin, given to 84% of registry patients receiving thrombolytic therapy and to 63% of the remainder, has been demonstrated to reduce rates of reinfarction and death after myocardial infarction whether or not thrombolytic therapy is used. 19 Although aspirin was used commonly in registry patients, it is surprising that its use was not even higher, given its proven effectiveness, low spectrum of side effects, and low cost.
Intravenous heparin, used in 97% of registry patients receiving thrombolytics and in more than half the remainder, has never been unequivocally demonstrated to improve longevity in myocardial infarction'135 but has been shown to preserve infarct vessel patency after rTPA therapy.36-38 The use of protocol-directed intravenous heparin in combination with rTPA in the recent GUSTO trial7 may explain, in part, the finding of a lower 30-day mortality with rTPA than with streptokinase-heparin regimens in that trial, whereas prior Intravenous nitroglycerin, used in 76% of thrombolytic recipients and 50% of the remainder, was reported in late 1993 not to improve survival of acute myocardial infarction. 43 meta-analysis suggesting that intravenous nitroglycerin might reduce mortality as much as 35%.1 Calcium channel blockers have not been proven "cardioprotective" after myocardial infarction44,45 and in some studies appeared to be harmful,4647 yet they were used in 30% of thrombolytic recipients in the registry and in 42% of all others. Although clinical trials involving more than 26 000 patients' 45 have confirmed the efficacy of f-blockers in limiting mortality and preventing recurrent ischemia after myocardial infarction, intravenous and oral fl-blockers were used in only 17% and 36%, respectively, of registry thrombolytic recipients and in 30% and 42%, respectively, of all others. The GUSTO investigators, on the other hand, used intravenous fl-blockers in 46% and oral P-blockers in 71% of patients with acute myocardial infarction. 7 The registry, therefore, reveals patterns of use of pharmacological therapy that, in the case of aspirin, 8f-blockers, and calcium channel blockers, seem inconsistent with the recommendations of recent clinical trials. However, analysis of trends from 1990 through 1993 suggests that usage of these agents may slowly be coming closer into line with trial recommendations (Fig 8) , as previously reported. 5 
Invasive Procedures
The role of postinfarction coronary arteriography remains controversial. 48 The availability of facilities for cardiac catheterization has been shown to correlate closely with the likelihood of their use after myocardial infarction.4951' Because the primary incentive for coronary arteriography is to identify lesions suitable for revascularization by angioplasty or bypass surgery, several recent trials have randomized patients after infarction between an "invasive strategy" of routine coronary arteriography followed by revascularization, if appropriate, and a "conservative strategy" of "watchful waiting," with arteriography and revascularization used only for patients with spontaneous or provocable ischemia.5' 5 None of the trials showed an advantage of the invasive approach in improving ventricular function, reducing the incidence of reinfarction, or reducing mortality up to 3 years after infarction. 54 If the "conservative" approach to postinfarction arteriography is followed, what frequencies of coronary arteriography, angioplasty, and bypass surgery are to be expected during the initial hospitalization? In the largest of the randomized studies, the Should We Intervene Following Thrombolysis? (SWIFT)52 trial and the TIMI phase II trial,5' coronary arteriography was used in the conservative groups in 13% and 33%, angioplasty in 3% and 13%, and bypass surgery in 2% and 7%, respectively. In the National Registry of Myocardial Infarction, coronary arteriography was used in 71% of thrombolytic recipients, angioplasty in 30%, and bypass surgery in 13%. These frequencies are markedly higher than would have been expected had the conservative policy of "watchful waiting" been followed.
Adverse Events
Patients treated with thrombolytic therapy in randomized trials are known to have higher rates of allergic reactions, bleeding, arrhythinias, and reinfarctionn1819 and these trends were confirmed in the registry (Table TABLE 3 Clinical Implications and Future Directions The National Registry of Myocardial Infarction suggests that, among the participating institutions, composing about 14% of all US hospitals, the results of recent clinical trials are being implemented in clinical practice in an inconsistent fashion. Although thrombolytic therapy is used in a substantial proportion of infarct patients, it is often withheld from elderly patients, in whom it may save the most lives, and from patients who do not reach the hospital immediately after symptom onset. For patients treated with thrombolytic therapy, the "door-to-drug time" is extraordinarily prolonged. Although adjunctive treatment with intravenous heparin and intravenous nitroglycerin is usually used, aspirin and }3-blockers appear to be underused and calcium channel blockers appear to be overused. Furthermore, it is evident that routine coronary arteriography after infarction followed by revascularization, if feasible, is the policy at many institutions, despite the findings of recent clinical trials showing that such invasive management offers no better short-or long-term outcome than a more conservative approach.
These observations should provide incentive for alterations in current practice patterns: expansion of the use of thrombolytic therapy, more rapid triage and treatment, more appropriate conjunctive pharmacotherapy, and a more rational utilization of invasive resources. As these or other changes begin to occur, the National Registry of Myocardial Infarction will be a valuable tool to detect and track such modifications and their outcome.
